Avinerve Xt Tablet -

Combined, symptom suppression and nutritional support may provide better clinical benefit than either alone in some patients.

Avinerve XT is a fixed-dose combination medicine formulated to manage neuropathic pain and nerve-related symptoms such as tingling, numbness, burning, and shooting pains. It pairs an anticonvulsant agent used for nerve pain with a B‑complex vitamin component intended to support nerve health and reduce neuropathy symptoms. avinerve xt tablet

Avinerve XT may interact with:

| Patient Category | Starting Dose | Titration/Adjustment | Maximum Dose | |------------------|--------------|----------------------|--------------| | Adults (≥ 18 y) with both hypertension & dyslipidaemia | 1 tablet (10 mg amlodipine / 20 mg atorvastatin) once daily (preferably in the morning) | - If BP target not reached after 2–4 weeks, consider adding a thiazide‑type diuretic or switching to higher‑strength FDC (if available).
- If LDL‑C target not met, consider adding ezetimibe or switching to higher‑strength statin FDC (e.g., Avinerve XT 10 /40 mg). | No formal “maximum” for this specific strength; however, total amlodipine ≤ 10 mg and atorvastatin ≤ 80 mg per day are recommended. | | Renal impairment (eGFR ≥ 30 mL/min/1.73 m²) | Same as adults | No dose adjustment required for amlodipine; atorvastatin dose may be maintained unless severe hepatic disease. | | Elderly (≥ 75 y) | Same as adults, monitor for edema & dizziness | Consider lower starting dose of amlodipine (5 mg) if frail; however, 10 mg is still FDA‑approved. | | Hepatic impairment | Contraindicated in Child‑Pugh C; use with caution in B | Reduce atorvastatin to 10 mg (use separate monotherapy) if ALT > 3× ULN. | | Interaction | Effect | Clinical Recommendation |

Administration Tips

| Interaction | Effect | Clinical Recommendation | |-------------|--------|--------------------------| | Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, HIV protease inhibitors) | ↑ Atorvastatin & amlodipine plasma levels (2‑4×) | Reduce atorvastatin to 10 mg or avoid combination; consider alternative antihypertensive. | | CYP3A4 inducers (rifampin, carbamazepine, St. John’s wort) | ↓ Atorvastatin exposure → loss of LDL‑C benefit | Avoid if possible; if necessary, increase atorvastatin dose up to 40 mg (separate dosing). | | Fibrates (gemfibrozil) | ↑ risk of myopathy/rhabdomyolysis | Avoid concomitant use; if required, monitor CK weekly. | | Niacin (high‑dose) | ↑ myopathy risk | Avoid or monitor CK closely. | | Macrolide antibiotics (erythromycin) | ↑ amlodipine levels → hypotension | Use alternative antibiotic or monitor BP closely. | | Antacids / PPIs | No clinically significant effect | No dose adjustment needed. | | Warfarin | Variable INR changes (statins may potentiate) | Check INR 2–3 days after initiation; adjust warfarin dose as needed. | | Digoxin | Minor ↑ digoxin levels via amlodipine‑mediated P‑glycoprotein inhibition | Monitor digoxin levels if on narrow therapeutic index dosing. | 3× ULN. | Administration Tips